Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal down2.430 -0.030 (-1.220%)
Others

31/07/2020 17:46

Sino Biopharm (01177) gets drug registration certificate

[ET Net News Agency, 31 July 2020] Sino Biopharmaceutical Limited (01177) announced
that "Tofacitinib Citrate Tablet" (brand name: Weijie), a drug for the treatment of
rheumatoid arthritis developed by the group, has obtained drug registration certificate
granted by the National Medical Products Administration of the People's Republic of China
and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for
Generic Drugs.
Tofacitinib Citrate Tablet is suitable for adult patients with moderately to severely
active rheumatoid arthritis for whom methotrexate does not work well or who are intolerant
of methotrexate. It can be used in combination with methotrexate or other non-biological
anti-rheumatic drugs to improve the condition. (RC)

Back to Others

Remark: Real time quote last updated: 18/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.